litlas
Log inCreate account

Joyce O’Shaughnessy

Active 1992–2025

195
Papers
45,451
Citations
96
h-index
184
i10-index

Citations

Citations per year for Joyce O’Shaughnessy1964: 2 citations1971: 2 citations1982: 1 citations1993: 2 citations1994: 3 citations1995: 10 citations1996: 12 citations1997: 9 citations1998: 7 citations1999: 5 citations2000: 9 citations2001: 7 citations2002: 23 citations2003: 45 citations2004: 51 citations2005: 61 citations2006: 84 citations2007: 115 citations2008: 115 citations2009: 147 citations2010: 201 citations2011: 217 citations2012: 251 citations2013: 249 citations2014: 251 citations2015: 233 citations2016: 222 citations2017: 262 citations2018: 318 citations2019: 1,069 citations2020: 1,372 citations2021: 1,750 citations2022: 1,930 citations2023: 1,792 citations2024: 2,827 citations2025: 1,718 citations2026: 35 citations1965–1970: no citations, so these years are not shown1972–1981: no citations, so these years are not shown1983–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,444 citing papers, 25.2% of this breakdownChina: 1,880 citing papers, 10.7% of this breakdownItaly: 1,123 citing papers, 6.4% of this breakdownUnited Kingdom: 883 citing papers, 5% of this breakdownGermany: 794 citing papers, 4.5% of this breakdownFrance: 755 citing papers, 4.3% of this breakdownSpain: 675 citing papers, 3.8% of this breakdownCanada: 557 citing papers, 3.2% of this breakdownJapan: 496 citing papers, 2.8% of this breakdownAustralia: 479 citing papers, 2.7% of this breakdownSwitzerland: 449 citing papers, 2.6% of this breakdownBelgium: 431 citing papers, 2.5% of this breakdown
0%25.2%Other 26.3%

Institutions

Fields

  • Medicine60.7%
  • Biochemistry, Genetics and Molecular Biology29%
  • Materials Science3.1%
  • Immunology and Microbiology2.5%
  • Engineering1.4%
  • Computer Science0.9%
  • Other2.4%

Topics

  • HER2/EGFR in Cancer Research7.6%
  • Advanced Breast Cancer Therapies7.5%
  • Breast Cancer Treatment Studies6.8%
  • Cancer Immunotherapy and Biomarkers4.7%
  • Cancer Treatment and Pharmacology4.2%
  • Cancer Genomics and Diagnostics3%
  • Other66.2%

Coauthors

All papers

Open in search
  1. Pembrolizumab for Early Triple-Negative Breast Cancer

    Authors: Peter Schmid, Javier Cortés, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Theodoros Foukakis, Peter A. Fasching, Fátima Cardoso, Michael Untch, Liyi Jia, Vassiliki Karantza, Jing Zhao, Gursel Aktan, Rebecca Dent, Joyce O’Shaughnessy - New England Journal of Medicine 2020 cited by 3,116

  2. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Authors: Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo - New England Journal of Medicine 2021 cited by 1,543

  3. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

    Authors: Peter Schmid, Javier Cortes, Rebecca Dent, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fatima Cardoso, Jay Andersen, Debra Patt, Michael Danso, Marta Ferreira, Marie-Ange Mouret-Reynier, Seock-Ah Im, Jin-Hee Ahn, Maria Gion, Sally Baron-Hay, Jean-François Boileau, Yu Ding, Konstantinos Tryfonidis, Gursel Aktan, Vassiliki Karantza, Joyce O’Shaughnessy - New England Journal of Medicine 2022 cited by 1,145

  4. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

    Authors: Gabriel N. Hortobagyi, Salomon M. Stemmer, Howard A. Burris, Yoon-Sim Yap, Gabe S. Sonke, Lowell Hart, Mario Campone, Katarina Petrakova, Eric P. Winer, Wolfgang Janni, Pierfranco Conte, David A. Cameron, Fabrice André, Carlos L. Arteaga, Juan P. Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O’Shaughnessy - New England Journal of Medicine 2022 cited by 713

  5. openalex_id:w4221085715

    Authors: Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Lowell L. Hart, Mario Campone, Katarína Petráková, Eric P. Winer, Wolfgang Janni, PierFranco Conte, David Cameron, Fabrice André, Carlos L. Arteaga, Juan Pablo Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O’Shaughnessy cited by 579

  6. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

    Authors: Stephen Johnston, Masakazu Toi, Joyce O’Shaughnessy, Priya Rastogi, Mario Campone, Patrick Neven, Chiun‐Sheng Huang, Jens Huober, Georgina Garnica Jaliffe, İrfan Çiçin, Sara M. Tolaney, Matthew P. Goetz, Hope S. Rugo, Elżbieta Senkus, Laura Testa, Lucia Del Mastro, Chikako Shimizu, Ran Wei, Ashwin Shahir, Marı́a Jesús Muñoz, Belén San Antonio, Valérie André, Nadia Harbeck, Miguel Martín - The Lancet Oncology 2022 cited by 566

  7. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Authors: Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy - New England Journal of Medicine 2016 cited by 2,009

  8. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

    Authors: Stephen R. D. Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martin, Zhi Min Shao, Qing Yuan Zhang, Jorge Luis Martinez Rodriguez, Mario Campone, Erika Hamilton, Joohyuk Sohn, Valentina Guarneri, Morihito Okada, Frances Boyle, Patrick Neven, Javier Cortés, Jens Huober, Andrew Wardley, Sara M. Tolaney, Irfan Cicin, Ian C. Smith, Martin Frenzel, Desirée Headley, Ran Wei, Belen San Antonio, Maarten Hulstijn, Joanne Cox, Joyce O’Shaughnessy, Priya Rastogi - Journal of Clinical Oncology 2020 cited by 986

  9. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

    Authors: Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan, Robert Iannone, Sarah A. Washkowitz, Robert M. Sharkey, William A. Wegener, Kevin Kalinsky - New England Journal of Medicine 2019 cited by 850

  10. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

    Authors: Aditya Bardia, Wells A. Messersmith, Ebenezer A. Kio, Jordan Berlin, Linda T. Vahdat, Gregory A. Masters, R Moroose, Alessandro D. Santin, Kevin Kalinsky, Vincent J. Picozzi, Joyce O’Shaughnessy, Jhanelle E. Gray, Takefumi Komiya, Joshua M. Lang, Jenny C. Chang, Alexander Starodub, David M. Goldenberg, Robert M. Sharkey, Pius Maliakal, Q. Hong, William A. Wegener, Trishna Goswami, Allyson J. Ocean - Annals of Oncology 2021 cited by 375

  11. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

    Authors: David Miles, Joseph Gligorov, Fabrice André, David Cameron, Andreas Schneeweiß, Carlos H. Barrios, Binghe Xu, Andrew Wardley, Diego Kaen, Livia Andrade, Semiglazov Vf, Mattea Reinisch, Shilpen Patel, Monika Patre, L. Morales, Sipahee Lal Patel, Manika Kaul, Teresa Barata, Joyce O’Shaughnessy, Q. Zhang, Binghe Xu, Zhimin Shao, Xiangyu Wang, Cuizhi Geng, Xingchen Yan, Zhongsheng Tong, Kunwei Shen, Yongmei Yin, Tao Sun, James Chih‐Hsin Yang, J Feng, Min Yan, Yan Wang, Qiang Liu, S. Zhang, Michelino De Laurentiis, Armando Santoro, Valentina Guarneri, Marco Colleoni, Clara Natoli, Laura Cortesi, Sabino De Placido, Lorenzo Gianni, Francesco Ferraù, Lorenzo Livi, Alberto Zambelli, Lucia Del Mastro, Giuseppe Tonini, Filippo Montemurro, Giulia Bianchi, R. Pedersini, Salvatore A. Del Prete, Giacomo Allegrini, Giuseppe Naso, Patrizia Vici, D. Loirat, Audrey Mailliez, Franck Priou, Olivier Trédan, F. Dalenc, Christophe Perrin, Joseph Gligorov, Morales-Pancorbo David, Nadine Dohollou, Luís Teixeira, Fabien Brocard, Antoine Arnaud, Suzette Delaloge, Jean‐Philippe Spano, Luigi Mansi, Livia Andrade, Fernanda Damian, José Luiz Pedrini, Sandra M. Aleixo, Roberto Hegg, R. Junior, Mattea Reinisch, Marcus Schmidt, C. Wenzel, E.‐M. Grischke, Andreas Schneeweiß, Marianne Just, Nadia Harbeck, Claudia Schumacher, Ubong Peters, Dorothea Fischer, Helmut Forstbauer, Rüdiger Liersch, Ellen Warner, Nathaniel Bouganim, C. T. Doyle, Julie Price Hiller, Ted Vandenberg, Michel Pavic, Andrew Robinson, Gloria Roldan Urgoiti, Nadia Califaretti, Ahmet Alacacıoğlu, M. Gumus, Bülent Yalçın and 68 more - Annals of Oncology 2021 cited by 729

  12. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

    Authors: Gabriel N. Hortobágyi, Salomon M. Stemmer, H.A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, M. Campone, Katarína Petráková, Kimberly Blackwell, Eric P. Winer, W Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, S. Mondal, Fei Su, Marshall G. Miller, Mohamed Elmeliegy, Caroline Germa, Joyce O’Shaughnessy - Annals of Oncology 2018 cited by 868

  13. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

    Authors: Sylvia Adams, P. Schmid, H. S. Rugo, EP Winer, D. Loirat, Ahmad Awada, D.W. Cescon, Hiromitsu Iwata, M. Campone, Rita Nanda, Rita L. Hui, Giuseppe Curigliano, D. Toppmeyer, Joyce O’Shaughnessy, Sherene Loi, Shani Paluch–Shimon, Antoinette R. Tan, Deborah Card, Jing Zhao, V. Karantza, Javier Cortés - Annals of Oncology 2018 cited by 795

  14. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

    Authors: Aditya Bardia, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H. Barrios, Joyce O’Shaughnessy, Hans Wildiers, Jean‐Yves Pierga, Qingyuan Zhang, Cristina Saura, Laura Biganzoli, Joohyuk Sohn, Seock‐Ah Im, Christelle Lévy, William Jacot, Natasha Begbie, Jun Ke, Gargi Patel, Giuseppe Curigliano - New England Journal of Medicine 2024 cited by 393

  15. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

    Authors: Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch, William M. Sikov, Hope S. Rugo, Mark D. McKee, Jens Huober, Mehra Golshan, Gϋnter von Minckwitz, David Maag, Danielle Sullivan, Norman Wolmark, Kristi McIntyre, José Ponce, Otto Metzger, Priya Rastogi, W. Fraser Symmans, Xuan Liu, Charles E. Geyer - The Lancet Oncology 2018 cited by 771

  16. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

    Authors: Peter Schmid, Javier Cortes, Rebecca Dent, Heather L. McArthur, Lajos Pusztai, Sherko Kümmel, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Seock‐Ah Im, Michael Untch, Peter A. Fasching, Marie‐Ange Mouret‐Reynier, Theodoros Foukakis, Marta Ferreira, Fátima Cardoso, Xuan Zhou, Vassiliki Karantza, Konstantinos Tryfonidis, Gursel Aktan, Joyce O’Shaughnessy - New England Journal of Medicine 2024 cited by 419

  17. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

    Authors: Aditya Bardia, Sara M. Tolaney, Kevin Punie, Delphine Loirat, Mafalda Oliveira, Kevin Kalinsky, Amelia Zelnak, Philippe Aftimos, Florence Dalenc, Sagar Sardesai, Erika Hamilton, Priyanka Sharma, Sabela Recalde, Eva Ciruelos Gil, T Traina, Joyce O’Shaughnessy, Javier Cortés, Mu‐Hung Tsai, Linda T. Vahdat, Véronique Dièras, Lisa A. Carey, Hope S. Rugo, David M. Goldenberg, Q. Hong, Martin Olivo, Loretta M. Itri, Sara A. Hurvitz - Annals of Oncology 2021 cited by 299

  18. Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

    Authors: William J. Gradishar, Sergei Tjulandin, Neville Davidson, Heather Shaw, Neil Desai, Paul Bhar, Michael Hawkins, Joyce O’Shaughnessy - Journal of Clinical Oncology 2005 cited by 2,132

  19. LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer

    Authors: Fátima Cardoso, Heather L. McArthur, Peter Schmid, Javier Cortés, Nadia Harbeck, Melinda L. Telli, David W. Cescon, Joyce O’Shaughnessy, Peter A. Fasching, Zhi-Min Shao, Delphine Loirat, Y.H. Park, María Ángeles Fernández, Z. Liu, Hiroyuki Yasojima, Yu Ding, L. Jia, Vassiliki Karantza, Konstantinos Tryfonidis, Aditya Bardia - Annals of Oncology 2023 cited by 134

  20. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer

    Authors: Priyanka Sharma, Shane R. Stecklein, Rachel Yoder, Joshua M. Staley, Kelsey Schwensen, Anne O’Dea, Lauren Nye, Deepti Satelli, Gregory Crane, Rashna Madan, Maura O’Neil, Jamie L. Wagner, Kelsey E. Larson, Christa Balanoff, Lyndsey J. Kilgore, Milind A. Phadnis, Andrew K. Godwin, Roberto Salgado, Qamar J. Khan, Joyce O’Shaughnessy - JAMA Oncology 2023 cited by 164

  21. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Authors: Nadia Harbeck, Priya Rastogi, Miguel Martín, Sara M. Tolaney, Zhimin Shao, Peter A. Fasching, Chiun‐Sheng Huang, Georgina Garnica Jaliffe, A. Tryakin, Matthew P. Goetz, Hope S. Rugo, Elżbieta Senkus, Laura Testa, Mariette Andersson, Kenji Tamura, Lucia Del Mastro, Guenther G. Steger, Hans Kreipe, Roberto Hegg, Joohyuk Sohn, Valentina Guarneri, Javier Cortés, E.P. Hamilton, Valérie André, Ran Wei, Susana Barriga, S. Sherwood, Tammy Forrester, Montserrat Muñoz-Mateu, Ashwin Shahir, Belén San Antonio, Sarah C. Nabinger, Masakazu Toi, Stephen Johnston, Joyce O’Shaughnessy, M.M. Jimenez, Stephen Johnston, F. Boyle, Guenther G. Steger, Patrick Neven, Zefei Jiang, Mario Campone, Jens Huober, Chikako Shimizu, I. Cicin, Andrew Wardley, Sara M. Tolaney, Gonzalo Gómez Abuin, J. J. Zarba, Elgene Lim, P. Sant, Naishun Liao, Bo Christiansen, Natalja Eigėlienė, J. Martin-Babau, Johannes Ettl, D. Mavroudis, Joanne Chiu, Katalin Boér, R. Nagarkar, Shani Paluch–Shimon, Luca Moscetti, Yoshiatsu Sagara, S.-B. Kim, Rui M. B. Maciel, Vivianne C. G. Tjan‐Heijnen, Reuben Broom, Aleksandra Łacko, M. Schenker, Nikita Volkov, Yoon Sim Yap, M.A. Coccia-Portugal, J. Ángel García Sáenz, Anne Andersson, Tai-Jong Chao, Erhan Gökmen, Hakan Harputluoğlu, O. Berzoy, Debra A. Patt, Heather L. McArthur, Helen K. Chew, Pavani Chalasani, Peter A. Kaufman, Karen L. Tedesco, Stephanie L. Graff - Annals of Oncology 2021 cited by 378

  22. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

    Authors: Priya Rastogi, Joyce O’Shaughnessy, Miguel Martín, Frances Boyle, Javier Cortés, Hope S. Rugo, Matthew P. Goetz, Erika Hamilton, Chiun‐Sheng Huang, Elżbieta Senkus, A. Tryakin, İrfan Çiçin, Laura Testa, Patrick Neven, Jens Huober, Zhimin Shao, Ran Wei, Valérie André, María del Mar Muñoz, Belén San Antonio, Ashwin Shahir, Nadia Harbeck, Stephen Johnston - Journal of Clinical Oncology 2024 cited by 204

  23. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

    Authors: Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortés, Véronique Dièras, Debra A. Patt, Hans Wildiers, Clifford A. Hudis, Joyce O’Shaughnessy, Esther Zamora, Denise A. Yardley, Martin Frenzel, Andrew Koustenis, José Baselga - Clinical Cancer Research 2017 cited by 683

  24. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

    Authors: Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond, Rebecca Moroose, Steven J. Isakoff, Alexander Starodub, Nikita Shah, Joyce O’Shaughnessy, Kevin Kalinsky, Michael J. Guarino, Vandana G. Abramson, Dejan Juric, Sara M. Tolaney, Jordan Berlin, Wells A. Messersmith, Allyson J. Ocean, William A. Wegener, Pius Maliakal, Robert M. Sharkey, Serengulam V. Govindan, David M. Goldenberg, Linda T. Vahdat - Journal of Clinical Oncology 2017 cited by 409